Skip to content
Back to Blog
Bio
2026-07-048 min read13

Ministry of Health & SMEs Joint Biohealth Investment-Linked R&D Support Up to 6B KRW: Full Application Guide

A strategic guide to the Ministry of Health and Welfare & SMEs' joint biohealth investment-linked R&D program, covering eligibility, evaluation criteria, and commercialization support for up to 6 billion KRW per project.

KITIM Consulting Team

What Is the Ministry of Health & SMEs Joint Biohealth Investment-Linked R&D Program?

In 2026, the Ministry of Health and Welfare and the Ministry of SMEs and Startups are jointly operating the 'Investment-Linked Technology Development Project (Policy-Designated Type)' — a composite support program designed to help promising biohealth companies and research institutions secure both R&D funding and commercialization capital simultaneously. Each selected project receives up to 6 billion KRW (approx. USD 4.4M) in R&D grants, with additional pathways to policy finance and private investment — a significant departure from conventional one-dimensional R&D subsidies.

The program reflects the Korean government's accelerated commitment to positioning biohealth as a national strategic industry. With the global biohealth market projected to grow at over 7% CAGR through 2030, the two ministries have joined forces to help domestic SMEs and bio-ventures overcome the twin barriers of early-stage R&D funding and commercialization capital.

Eligibility and Supported Technology Areas

Who Can Apply

  • SMEs, venture companies, and startups: supported across all growth stages, from seed to scale-up
  • Universities and public research institutions: given priority consideration when forming industry-academia-research consortia
  • Large corporations and mid-sized companies with annual revenue exceeding KRW 150 billion are generally excluded
  • Eligible Technology Areas

  • Pharmaceuticals: first-in-class novel drugs, improved drugs, biologics (cell/gene therapy, antibody drugs)
  • Medical devices: AI-powered diagnostics, regenerative medicine devices, in vitro diagnostics (IVD)
  • Digital health: digital therapeutics (DTx), medical AI software, telemedicine platforms
  • Restrictions on Duplicate Funding

    Applications covering the same project scope as an already-funded national R&D project are generally ineligible. However, follow-on development stages (Phase expansion) or new indication studies may qualify as separate projects — always verify with the administering agency before applying.

    Key Evaluation Criteria

    The most distinctive feature of this program is that investment attractiveness is explicitly embedded in the evaluation framework. While conventional R&D programs focus primarily on technological maturity and IP outputs, this program uses three balanced pillars:

  • Technology (30%): originality of core IP, TRL 4 or above, patent portfolio strength
  • Market potential (30%): addressable market size, differentiation vs. competing products, global scalability
  • Commercialization feasibility (40%): prior investment history or signed LOIs, specificity of the commercialization roadmap, management team's business development capability
  • Notably, evaluation panels include private venture capitalists and technology finance specialists, meaning your proposal will be assessed through the lens of 'would this company actually attract investment?' Your business plan must therefore go beyond technical description to articulate a clear market penetration strategy and investment scenario.

    Technology Commercialization Strategy Checklist

  • [ ] Quantified 3-year revenue scenarios (conservative / base / optimistic)
  • [ ] IP defense strategy (core patents + design-around)
  • [ ] Clinical and regulatory roadmap (milestones and cost estimates by phase)
  • [ ] Key partnership agreements or LOIs attached
  • [ ] Team composition and external advisory board
  • Leveraging the Commercialization Support Ecosystem

    Beyond the grant itself, this program opens multiple commercialization pathways.

    Technology Transfer and Licensing

    Through linkages with the Korea Technology Transfer Center (KTTC) and IP marketplaces, selected companies gain access to technology licensing matchmaking with large corporates or overseas biohealth firms. License-out transactions completed during the project term earn additional commercialization performance credits.

    Global Expansion Support

  • KOTRA Biohealth Export Program: overseas partner discovery, local regulatory guidance
  • K-BIO Global IR: support for participation in major international expos such as BIO USA and BioJapan
  • FDA/EMA Pre-consultation: partial funding for regulatory strategy development at the global clinical design stage
  • Strengthen Your Proposal with KITIM Consulting

    The Investment-Linked R&D program demands both volume and quality in its application documents. Crafting a business plan that coherently integrates technology, market, and investment in a single narrative is a genuinely complex task.

    KITIM provides end-to-end support — from R&D project planning and business plan writing to technology evaluation preparation and investment strategy development — all under one roof. Our consultants, specializing in pharmaceuticals, medical devices, and digital health respectively, review your application from the evaluator's perspective and co-develop a commercialization strategy report aligned with real VC investment standards.

    Contact KITIM today for a free initial consultation, and our specialists will walk you through an eligibility assessment and document preparation timeline tailored to your situation.

    BiohealthGovernmentSupportRDFundingInvestmentLinkedMOTIEMHWTechCommercialization

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.